Literature DB >> 11260086

Stem cell transplantation from HLA-matched related donor for Fanconi's anaemia: a retrospective review of the multicentric Italian experience on behalf of AIEOP-GITMO.

C Dufour1, R Rondelli, F Locatelli, M Miano, G Di Girolamo, A Bacigalupo, C Messina, F Porta, A Balduzzi, A P Iorio, E Buket, E Madon, A Pession, G Dini, P Di Bartolomeo.   

Abstract

Twenty-seven consecutive Italian patients with Fanconi's anaemia (FA) underwent stem cell transplantation (SCT) from an HLA-matched related donor in 10 Italian centres of the Associazione Italiana Ematologia ed Oncologia Pediatrica (AIEOP), Gruppo Italiano di Trapianto di Midollo Osseo (GITMO). Twenty-two patients (81.5%) were conditioned with low-dose (median 20 mg/kg) cyclophosphamide (Cy) and thoraco-abdominal or total body irradiation (median dose 500 cGy), five patients (18.5%) with high-dose Cy (median 120 mg/kg). Graft-vs.-host disease (GVHD) prophylaxis was carried out with cyclosporin A in 26 cases; methotrexate (MTX) was added in eight cases. One patient received MTX alone. The median follow-up was 36 months. Ninety-two percent of patients (25 out of 27) engrafted, grade II and III acute GVHD occurred in 28% and 8% of patients, respectively, with chronic GVHD in 12.5%. Conditioning-related toxicity was mild: 4% of patients had grade III mucositis, 7.4% had grade II haemorrhagic cystitis, 14.8% had grade III liver toxicity and 11.1% had grade III renal toxicity. Transplant-related mortality at 12 months was 19.2%, survival at 36 months was 81.5%, with a median Karnofsky score of 100%. No late tumours occurred after a mean follow-up of the survivors of 5 years. None of the studied variables significantly affected the survival, including conditioning regimen, acute GVHD and clinical non-haematological phenotype. Among the studied variables, only conditioning regimens containing high-dose Cy and the presence of genital abnormalities were significantly (P < 0.05) associated with an increased rate of acute GVHD. Our study demonstrates that the Italian FA patients undergoing SCT from an HLA-matched related donor have a very good outcome. These patients, when compared with others of different ethnic origin who underwent allogeneic bone marrow transplantation, showed a less severe non-haematological phenotype, raising the possibility that this milder phenotype may have, at least in part, contributed to the outcome. Our data may provide a useful tool for further studies aiming to correlate genotype with phenotype.

Entities:  

Mesh:

Year:  2001        PMID: 11260086     DOI: 10.1046/j.1365-2141.2001.02572.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

Review 1.  Hematopoietic cell transplantation in Fanconi anemia: current evidence, challenges and recommendations.

Authors:  Christen L Ebens; Margaret L MacMillan; John E Wagner
Journal:  Expert Rev Hematol       Date:  2016-12-21       Impact factor: 2.929

2.  Comparable Outcomes after HLA-Matched Sibling and Alternative Donor Hematopoietic Cell Transplantation for Children with Fanconi Anemia and Severe Aplastic Anemia.

Authors:  Christen L Ebens; Todd E DeFor; Rebecca Tryon; John E Wagner; Margaret L MacMillan
Journal:  Biol Blood Marrow Transplant       Date:  2017-12-02       Impact factor: 5.742

Review 3.  Stem cell gene therapy for fanconi anemia: report from the 1st international Fanconi anemia gene therapy working group meeting.

Authors:  Jakub Tolar; Jennifer E Adair; Michael Antoniou; Cynthia C Bartholomae; Pamela S Becker; Bruce R Blazar; Juan Bueren; Thomas Carroll; Marina Cavazzana-Calvo; D Wade Clapp; Robert Dalgleish; Anne Galy; H Bobby Gaspar; Helmut Hanenberg; Christof Von Kalle; Hans-Peter Kiem; Dirk Lindeman; Luigi Naldini; Susana Navarro; Raffaele Renella; Paula Rio; Julián Sevilla; Manfred Schmidt; Els Verhoeyen; John E Wagner; David A Williams; Adrian J Thrasher
Journal:  Mol Ther       Date:  2011-05-03       Impact factor: 11.454

Review 4.  Finding the needle in the hay stack: hematopoietic stem cells in Fanconi anemia.

Authors:  Lars U W Müller; David A Williams
Journal:  Mutat Res       Date:  2009-04-02       Impact factor: 2.433

5.  Twenty years of the Italian Fanconi Anemia Registry: where we stand and what remains to be learned.

Authors:  Antonio M Risitano; Serena Marotta; Rita Calzone; Francesco Grimaldi; Adriana Zatterale
Journal:  Haematologica       Date:  2015-12-03       Impact factor: 9.941

6.  Fanconi anemia - learning from children.

Authors:  Johanna Svahn; Carlo Dufour
Journal:  Pediatr Rep       Date:  2011-06-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.